Open Access
Research Article
Issue
Parasite
Volume 24, 2017
Article Number 34
Number of page(s) 11
DOI https://doi.org/10.1051/parasite/2017035
Published online 29 September 2017
  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7, 356-371. [CrossRef] [PubMed]
  2. Brasil MS Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. 2017. Manual de Vigilância da Leishmaniose Tegumentar [electronic resource]. SVS/MS: Brasília. 190 p. 2nd Edition. Available from: http://www.dive.sc.gov.br/conteudos/publicacoes/17_0093_M_e_C.pdf.
  3. World Health Organization. Essential leishmaniasis maps. [Accessed 5 January 2016]. http://www.who.int/leishmaniasis/leishmaniasis_maps/en/.
  4. Deps PD, Viana MC, Falqueto A, Dietze R. 2000. Avaliação comparativa da eficácia e toxicidade do antimoniato de N-metil-glucamina e do estibogluconato de sódio BP88 no tratamento da leishmaniose cutânea localizada. Revista da Sociedade Brasileira de Medicina Tropical, 33, 535-543. [CrossRef] [PubMed]
  5. Teixeira AC, Paes MG, Guerra JO, Prata A, Silva-Vergara ML. 2008. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Revista do Instituto de Medicina Tropical de São Paulo, 50, 157-160. [CrossRef]
  6. Antônio LF, Fagundes A, Oliveira RVC, Pinto PG, Bedoya-Pacheco SJ, Vasconcellos Ede C, Valete-Rosalino MC, Lyra MR, Passos SR, Pimentel MI, Schubach Ade O. 2014. Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis. Revista do Instituto de Medicina Tropical de São Paulo, 56, 375-380. [CrossRef]
  7. Schubach AO, Marzochi KB, Moreira JS, Schubach TM, Araújo ML, Vale AC, Passos SR, Marzochi MC. 2005. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumineantimoniate. Revista da Sociedade Brasileira de Medicina Tropical, 38, 213-217. [CrossRef] [PubMed]
  8. Pacheco RS, Martinez JE, Valdemara AL, Momen H, Saravia NG. 1995. Genotypic polymorphisms in experimental metastatic dermal leishmaniasis. Molecular and Biochemical Parasitology, 69, 197-209. [CrossRef] [PubMed]
  9. Cupolillo E, Brahim LR, Toaldo CB, de Oliveira-Neto MP, de Brito ME, Falqueto A, de Farias Naiff M, Grimaldi G Jr. 2003. Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. Journal of Clinical Microbiology, 41, 3126-3132. [CrossRef]
  10. Miles MA, Llewellyn MS, Lewis MD, Yeo M, Baleela R, Fitzpatrick S, Gaunt MW, Mauricio IL. 2009. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future. Parasitology, 136, 1509-1528. [CrossRef] [PubMed]
  11. Pena SDJ, Barreto G, Vago AR, De Marco L, Reinach FC, Dias Neto E, Simpson AJ. 1994. Sequence-specific “gene signatures” can be obtained by PCR with single specific primers at low stringency. Proceedings of National Academy of Science of USA, 91, 1946-1949. [CrossRef]
  12. Baptista C, Schubach AO, Madeira MF, Leal CA, Pires MQ, Oliveira FS, Conceição-Silva F, Rosalino CM, Salgueiro MM, Pacheco RS. 2009. Leishmania (Viannia) braziliensis genotypes identified in lesions of patients with atypical or typical manifestations of tegumentary leishmaniasis: evaluation by two molecular markers. Experimental Parasitology, 121, 317-322. [CrossRef] [PubMed]
  13. Oliveira FS, Valete-Rosalino CM, Pacheco SJ, Costa FA, Schubach AO, Pacheco RS. 2012. American tegumentary leishmaniasis caused by Leishmania (Viannia) braziliensis: assessment of parasite genetic variability at intra- and inter-patient levels. Parasites & Vectors, 6, 189. [CrossRef]
  14. Oliveira FS, Valete-Rosalino CM, Schubach A de O, Pacheco RS. 2010. kDNA minicircle signatures of Leishmania (Viannia) braziliensis in oral and nasal mucosa from mucosal leishmaniasis patients. Diagnostic Microbiology and Infectious Disease, 66, 361-365. [CrossRef] [PubMed]
  15. Cupolillo E, Grimaldi GJ, Momen H. 1994. A general classification of new world Leishmania using numerical zymotaxonomy. American Journal of Tropical Medicine and Hygiene, 50, 296-311. [CrossRef]
  16. De Bruijn MH, Barker DC. 1992. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Tropica, 52, 45-58. [CrossRef] [PubMed]
  17. Minodier P, Parola P. 2007. Cutaneous leishmaniasis treatment. Travel Medicine and Infectious Diseases, 5, 150-158. [CrossRef]
  18. Grogl M, Oduola AM, Cordero LD, Kyle DE. 1989. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Experimental Parasitology, 69, 78-90. [CrossRef] [PubMed]
  19. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. 2006. Resistance to antimony and treatment failure in Human Leishmania (Viannia) infection. Journal of Infectious Diseases, 193, 1375-1383. [CrossRef]
  20. Lee ST, Tarn C, Chang KP. 1993. Characterization of the switch of kinetoplast DNA minicircle dominance during development and reversion of drug resistance in Leishmania. Molecular and Biochemical Parasitology, 58, 187-203. [CrossRef] [PubMed]
  21. Simpson L. 1987. The mitochondrial genome of kinetoplastid protozoa: genomic organization, transcription, replication, and evolution. Annual Review of Microbiology, 41, 363-382. [CrossRef] [PubMed]
  22. Lee SY, Lee ST, Chang KP. 1992. Transkinetoplastidy-a novel phenomenon involving bulk alterations of mitochondrion-kinetoplast DNA of a trypanosomatid protozoan. Journal of Protozoology, 39, 190-196. [CrossRef]
  23. Schriefer A, Schriefer AL, Góes-Neto A, Guimarães LH, Carvalho LP, Almeida RP, Machado PR, Lessa HA, de Jesus AR, Riley LW, Carvalho EM. 2004. Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American Tegumentary Leishmaniasis. Infection and Immunity, 72, 508-514. [CrossRef] [PubMed]
  24. Kuhls K, Cupolillo E, Silva SO, Schweynoch C, Boité MC, Mello MN, Mauricio I, Miles M, Wirth T, Schönian G. 2013. Population structure and evidence for both clonality and recombination among Brazilian strains of the subgenus Leishmania (Viannia). PLoS Neglected Tropical Diseases, 7, 2490. [CrossRef] [PubMed]
  25. Romero GA, Guerra MV, Paes MG, Cupolillo E, Bentin Toaldo C, Macêdo VO, Fernandes O. 2001. Sensitivity of the polymerase chain reaction for the diagnosis of cutaneous leishmaniasis due to Leishmania (Viannia) guyanensis. Acta Tropica, 79, 225-229. [CrossRef]
  26. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J, Dujardin JC, Arevalo J, Chappuis F. 2008. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clinical Infectious Diseases, 46, 223-231. [CrossRef]
  27. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. 1997. A low dose antimony treatment in 159 patients with American cutaneous leishmaniasis. Extensive follow-up studies (up to 10 years). American Journal of Tropical Medicine and Hygiene, 57, 651-655. [CrossRef]
  28. Rodrigues AM, Hueb M, Santos TA, Fontes CJ. 2006. Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate. Revista da Sociedade Brasileira de Medicina Tropical, 39, 139-145. [CrossRef] [PubMed]
  29. Sacks D, Noben-Trauth N. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nature Reviews Immunology, 2, 845-858. [CrossRef] [PubMed]
  30. Gurung P, Karki R, Vogel P, Watanabe M, Bix M, Lamkanfi M, Kanneganti TD. 2015. An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. Journal of Clinical Investigation, 125, 1329-1338. [CrossRef]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.